Original Article

Prevalence of Itch in German Schoolchildren: A Population-based Study

Grigorios THEODOSIOU1#, Theresa NISSEN2#*, Elke WEISSHAAR1, Sandra PLACHTA-DANIELZIK4, Matthias AUGUSTIN5, Sonja STÄNDER6 Laura B. VON KOBYLETZKI7,8 and Regina FÖLSTER-HOLST2#

1Department of Dermatology and Venereology, Lund University, Malmö, Sweden, 2Department of Dermatology-Venereology-Allergology, University Hospital of Schleswig-Holstein, Kiel, 3Occupational Dermatology, Department of Dermatology, Ruprecht-Karls University, Heidelberg, 4Institute of Human Nutrition and Food Science, Christian-Albrechts University, Kiel, 5Department of Dermatology-Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, 6Department of Dermatology, Center for Chronic Pruritus, University Hospital Münster of the Westphalian Wilhelms-University, Münster, Germany, 7Department of Occupational and Environmental Dermatology, Lund University, Malmö and 8School of Medical Sciences Sciences Örebro, Örebro University, Sweden

These authors contributed equally to this work and #share first authorship and *share last authorship.

Itch is a common symptom, but there is limited evidence on the prevalence of itch in children. The aim of this study was to assess the prevalence of itch in schoolchildren. A questionnaire was developed by experts in the field and based on a literature search. The questionnaire was applied in a pilot study of 25 consecutively selected paediatric patients and their parents. It confirmed the high content validity of the questionnaire, and the questionnaire was comparable to hospital records regarding chronic itch (n = 19, mean consistency 89.47%). The questionnaire was distributed among German schoolchildren in 9/12 randomly selected primary schools in Kiel, Germany. Of 1,722 invited students, 443 schoolchildren aged 6–10 years participated, and 26.2% (n = 116) reported itch. The prevalence of acute itch was 20.0% (n = 87), and 14.7% (n = 65) reported chronic itch. Reduced sleep and mood were often related to chronic itch. This study demonstrated that itch is a common symptom in German schoolchildren.

Key words: itch; pruritus; epidemiology; quality of life; prevalence.

Accepted Apr 8, 2022; Epub ahead of print Apr 8, 2022

Acta Derm Venereol 2022; 102: adv00718.

DOI: 10.2340/actadv.v102.1063

Corr: Grigorios Theodosiou, Department of Dermatology and Venereology, Lund University, SE-205 02 Malmö, Sweden. E-mail: gregtheodosiou@yahoo.com

Itch is a major contributor to an estimated 33.7 million-person years lived with disability caused by dermatological conditions (1). Itch is associated with sleeping problems, reduced quality of life (2) and increased costs for individuals and society (3). To the best of our knowledge, there are no population-based studies on the prevalence of acute and chronic itch in schoolchildren.

Atopic dermatitis (AD) is common in children and is reported to be the main underlying condition in itch in children (3–5); other aetiologies, such as systemic conditions, do not appear to play a major role (3). Itch is a mandatory diagnostic criterion in validated assessments for AD in children and adults (6, 7). Itch was self-reported or parent-reported in ~91–95% of children and adults with AD (6); nocturnal itch was reported in approximately 32% of children with AD (8).

Furthermore, there are limited data on general population-based samples regarding the intensity of itch in children. In addition to intensity, a recent qualitative study emphasized that itch quality, duration, and triggers were important characteristics in understanding and managing itch, and stressed the need for more comprehensive measures of paediatric itch (9). Therefore, general population-based studies on the prevalence and characteristics of itch in the paediatric population are highly warranted.

In epidemiological population-based studies and clinical practice, itch assessments via well-constructed, validated questionnaires are valuable. Validated questionnaires assessing itch prevalence exist for adults (10–12), but not for children. Understanding the prevalence and burden of itch in the paediatric population is important for decision-makers and healthcare professionals regarding public health policies and resources.

The main aim of this study was to assess the prevalence of acute and chronic itch in a general population-based sample of schoolchildren aged 6–10 years in Kiel, Germany. A questionnaire was developed and initial validation performed. The intensity of itch, relationship between itch and quality of life, and self-reported related conditions were also assessed.

At the time of this study there was no validated tool for assessing itch in the general population of schoolchildren. To the best of our knowledge, no method exists for as-

SIGNIFICANCE

The aim of this work was to assess how common itch is in schoolchildren in Germany. A questionnaire was developed and distributed to schoolchildren between 6 and 10 years of age in Kiel, Germany. 1 in 5 of the children had itch and 1 in 7 had chronic itch (itch lasting over 6 weeks). Moreover, chronic itch was associated with reduced quality of life in schoolchildren in terms of impaired sleep and mood disorders.
sessing the prevalence and intensity of itch in children up to 10 years old.

MATERIALS AND METHODS

This study consists of 2 parts: (i) questionnaire construction and validation; and (ii) itch prevalence assessment.

After an expert panel discussion and an extensive literature search, a draft questionnaire was designed by consensus discussion (12–19) and the assessment of the prevalence was based on the only validated study in adults, by Matterne et al. (12). The chosen questions were adapted and simplified to be suitable for children and their parents (Appendix SI). The importance of additional questions was discussed; it was decided to evaluate family and personal histories of atopic conditions, demographic information, possible underlying conditions of itch, itch duration, itch intensity localization, disease-specific quality of life, and itch treatments. In detail, the prevalence of underlying itch-related comorbidities, such as AD, xerosis cutis, urticaria, scabies, pediculosis capitis, and other skin diseases, was assessed by the question, “were you/ was your child diagnosed by a physician with 1 or several of the following diseases?” The structure and detailed questions of the questionnaire, and the validation part of the study, are shown in Appendix SI.

For prevalence of itch, the questions for the prevalence of acute itch were: Children’s Acute Itch (CAI): Does your child experience itch? Now or within the last 24 hours? Within the last 7 days? Within the last 6 weeks? The final questions for the prevalence of chronic itch were: Children’s Chronic Itch (CCI): Did your child ever experience chronic itch (≥3 days per week over a period of ≥6 weeks)? No; yes, within the last 24 hours; yes, within the last 12 months; yes, but more than 12 months ago. The caregivers/children had to answer “yes” to at least one of the questions regarding the occurrence of itch for it to be classified as acute/chronic itch. The questions confirmed the presence of itch and the period in which itch developed.

To assess the itch intensity, the visual analogue scale (VAS) was adopted using smileys/emojis with different facial expressions were graded in 5 “degrees”, from “very happy” to “very sad”). The intensity of acute itch was assessed with a VAS scale (from 0=no itch to 10=maximum itch) adopted for children using smileys in 5 categories, as described above. The intensity of chronic itch was also assessed using the smiley VAS.

Data on the area affected and itch-related quality of life (QoL) were also collected. For the symptom-specific assessment of QoL, the ItchyQoL questionnaire was used, translated into German (20). The ItchyQoL is a validated, itch-specific assessment that measures the degree to which itch affects QoL in terms of 3 dimensions: symptoms, functioning, and emotions. A higher score indicates a greater adverse impact on QoL (19).

A silhouette line drawing, which is commonly used in dermatological assessments of skin diseases, was applied to assess the location of itch (15). The children/caregivers marked the affected body sites.

Study procedures

Among all 32 primary schools in Kiel in the federal state of Schleswig-Holstein, 12 were randomly selected. After approval by the ethics committee and school authorities of Schleswig-Holstein, the project was presented to the 12 selected schools. Of these, 9 agreed to participate. All children in the first to fourth grades (age range 6–10 years) were invited to participate. Thus, more than 1,700 eligible schoolchildren were invited to answer the survey in September 2016 (Fig. S1). The questionnaires were distributed to the students, with consent forms to be signed by the parents and children. The completed questionnaires from the families who gave their consent were collected. The questionnaires were anonymized and entered into an electronic database in the Clinic of Dermatology, University Hospital, in Kiel (Fig. S1).

Inclusion/exclusion criteria

Inclusion criteria for the second part of the study were patients aged 6–10 years and signed informed consent. Exclusion criteria: age >10 years and <6 years at the time of the survey and lack of legal guardian consent.

Statistical analysis

For the first part, the questionnaire validity, content validity, and feasibility were assessed by qualitative analysis. The reliability, item distribution characteristics, mean agreement between itch questionnaire results and medical records, and test-retest reliability were calculated. Differences between groups (children diagnosed with AD vs other conditions) were tested using the Mann–Whitney U test. For itch intensity, the item distribution characteristic means, standard deviation (SD), median, interquartile range (IQR), and floor and ceiling effects were assessed. Furthermore, Spearman’s test was used to assess correlations of the itch prevalence and intensity with each parameter of the QoL and the strength of chronic itch in the test-retest reliability evaluation.

In the second part of the study, cross-tabulation, means, and medians were used to describe the study population. The distribution of the variables was assessed. For the daytime intensity of itch, night-time intensity of itch, relationships, and QoL relationships, the non-parametric Wilcoxon signed-rank test (non-parametric test for paired-samples) was used. For the intensity of itch and QoL, the (non-parametric) Mann–Whitney U test was used regarding sex and underlying diseases.

For all other relationships, the χ² test was used. For n < 5, Fisher’s exact test was used. Spearman’s Rho test was used to assess correlations among QoL, chronic itch strength, and itch area and evaluate age reliability. Bonferroni’s correction was used to adjust for multiple comparisons. A p-value lower than 0.05 or 95% confidence intervals (95% CI) not including 1.00 indicated statistical significance.

Statistical analysis was performed with Stata Statistical Software: Release 16 (StataCorp LP, College Station, TX, USA).

Power calculation

For the power calculation, 1,700 individuals with an estimated itch prevalence of 15.0%, CI of 3.0%, and expected response rate of 35.0% should be sufficient to estimate the prevalence of itch in patients with AD with a power of 80.0%.

Based on these statistical requirements, 12/32 primary schools in Kiel, Northern Germany, were randomly selected to participate. Private schools were not included, and the random selection did not consider any other variables.

Ethics

Ethical approval from the Kiel regional ethics committee was obtained at the regional research ethics committee in Kiel, Germany (registration number A112/14). All participants provided informed consent after receiving a comprehensive written explanation of the aims of the study. The study was conducted in full accordance with the World Medical Association’s Declaration of Helsinki.
RESULTS

Content validity and feasibility
To assess content validity, 25 patients participated, along with physicians, non-experts, and parents. The test–retest was performed by 33 individuals: 23 students from 1 of the participating schools in Kiel and 10 patients from the department. The psychometric measures were assessed in 19 patients.

The 25 patients and their parents found that the questionnaire was understandable and relevant to the prevalence and intensity of acute and chronic itch. The feasibility of the questionnaire was assessed as high. It took a mean of 7.6 min to answer all itch-related and background questions.

Test–retest reliability
The mean agreement of the CCI including the questions regarding comorbidities and background factors, was 0.85 (95% CI 0.59–1.00). For the VAS, the non-parametric Spearman correlation was high for nocturnal itch for the test–retest reliability (c=0.67).

Validity
The prevalence of chronic itch assessed by the questionnaire was well correlated with medical records in the 19 patients assessed. The itch of all participants could be confirmed by patient records (mean consistency 89.47%).

The test performance was equally high across all self-reported conditions. Regarding the mean, SD, median, and IQR, the measurements of itch intensity and floor and ceiling effects were acceptable. The intensity of acute itch changed (either increased or decreased) in 64% (95% CI 35–87%).

Prevalence of itch
To assess the prevalence of itch, 9/12 invited schools participated. Among all children invited (n=1,722), 443 answered the questionnaire, including 48.6% females (n=215) and 51.4% males (n=227). The response rate was 25.7%. The median age was 8 years. Most participants (98.9%) were born in Germany, and 21% had no siblings. The characteristics of the studied population are shown in Table SI.

![Table I. Prevalence of itch in German schoolchildren aged 6–10 years](image)

The total prevalence of itch was 26.2% (95% CI 19–36%) (n=116). The prevalence of acute itch and chronic itch was 20.0% (95% CI 12–29%) (n=87) and 14.7% (95% CI 7.0–26%) (n=65), respectively. There were no differences in the itch prevalence by sex or age (Table I).

A total of 21.2% (n=94) developed itch within the last 6 weeks, with 10.6% (n=47) having itch on the day of the assessment. In addition, 15.1% (n=67) reported itch within the last week. There were no differences in age or sex.

Chronic itch was reported within the previous 24 h by 1.8% (n=8/443), within the last year by 10.0% (n=44/443), and for more than 1 year by 4.7% (n=21/443). There were no differences in age or sex.

Itch intensity
The prevalence of itch assessed by VAS scores showed a mean standard deviation; IQR: interquartile range.

The intensity of chronic itch in the daytime was higher than that of nighttime, with no significant difference between boys and girls (Table I).

Regarding chronic itch (n=65), the mean intensity was 3.73, with a median [IQR] of 4.0 [3.0, 4.0], with no significant difference between daytime and night-time itch and between boys and girls (Table II).

The intensity of chronic itch in the daytime was higher in individuals with AD-related chronic itch compared
with those with non-AD-related chronic itch (Mann–Whitney $U$ test). For acute itch, itch severity did not differ between individuals with and without AD ($p<0.05$, data not shown).

**Itch localization**

Of the total body surface area (BSA), a mean of 8.7% was affected by acute itch, with a median [IQR] of 3.3% [2.3, 9.0] (Table SII). The scalp was the most frequently affected site (28.9%, $n=11$), followed by the arm flexures at 21.1% ($n=8$). On the trunk, the abdomen was the most affected area. On the upper extremities, acute itch mainly affected the flexures. On the lower extremities, the dorsal side of the foot and extensor side of the upper and lower leg were mainly affected (Table SIII).

For chronic itch, a mean of 8.2% of BSA was affected (Table SII). The flexural sides of the upper and lower extremities, lower back, and abdomen were predominantly affected (Table SIII).

**Itch and quality of life**

Itch was related to a decreased QoL; sleep and mood were disturbed in individuals with chronic itch compared with individuals without chronic itch (Table III). For individuals with itch, mood was more disturbed than concentration or leisure time, and concentration was disturbed less than sleep. Chronic itch in genital regions ($p<0.001$) was more closely related to mood disturbances than itch in other regions (i.e. not sensitive sites). Facial itch tended to be related to decreased concentration ($p=0.015$).

Concentration was better in individuals who reported chronic itch with AD and/or xerosis cutis compared with individuals with chronic itch, but without either AD or xerosis ($p<0.05$). Sleep and mood were decreased in individuals with chronic itch related to AD compared with those with chronic itch not related to AD (Mann–Whitney $U$ test, $p<0.05$). The presence of a comorbid condition in addition to AD did not worsen the QoL or intensity of chronic itch (Mann–Whitney $U$ test, $p<0.05$, data not shown).

All dimensions of the QoL measure (sleep, concentration, leisure, mood) were significantly correlated with itch intensity (Table III).

**Itch treatments**

Most of the 62 children experiencing chronic itch 85.5% ($n=53$) were treated by paediatricians ($n=44$, 71%) and dermatologists ($n=31$, 50%), followed by general practitioners ($n=4$, 6.5%) or other doctors ($n=1$, 1.6%). Treatment was primarily topical corticosteroids and calcineurin inhibitors. Some patients were treated with antihistamines and systemic corticosteroids. Homeopathy, bioresonance, acupuncture, and natural remedies were also used (Table IV).

**DISCUSSION**

This is the first population-based study on the prevalence of acute and chronic itch in schoolchildren from randomly selected primary schools. This study revealed several important findings. Most importantly, the prevalence of itch in schoolchildren aged 6–10 years was high. Approximately 25% reported itch; 20% had acute itch, and >14% reported chronic itch. The study also showed that itch was associated with impaired QoL in terms of reduced sleep and mood.

The content validity and feasibility assessment of the questionnaire used in this study showed good content validity, feasibility, and reliability. Correlation of the questionnaire with hospital records was also good. The questionnaire appeared to be useful for several self-reported underlying conditions related to itch, and thus can be used in population-based setting and may be useful in epidemiological research.

### Table III. Relationship between chronic itch and dimensions of the self-reported quality of life

| Sex      | Quality of life | Sleep | Concentration | Leisure time |
|----------|-----------------|-------|---------------|--------------|
| Male     |                 |       |               |              |
| $n=31$   | $n=31$          | $n=25$| $n=30$        |              |
| Mean 2.53* | Mean 2.45     | Mean 1.92* | Mean 2.23    |              |
| SD 0.99  | SD 1.15        | SD 0.91 | SD 0.90     |              |
| Median 3.0 | Median 2.0   | Median 2.0 | Median 2.0    |              |
| IQR 2.0–3.0 | IQR 1.0–4.0 | IQR 1.0–3.0 | IQR 2.0–3.0  |              |
| Female   |                 |       |               |              |
| $n=29$   | $n=30$         | $n=28$| $n=29$        |              |
| Mean 2.72* | Mean 2.68     | Mean 2.11* | Mean 2.43    |              |
| SD 0.88  | SD 1.28        | SD 1.10 | SD 0.98     |              |
| Median 3.0 | Median 3.0   | Median 2.0 | Median 2.5    |              |
| IQR 2.0–3.0 | IQR 1.0–4.0 | IQR 1.0–3.0 | IQR 2.0–3.0  |              |
| Total    | $n=60$         | $n=61$| $n=53$        | $n=59$       |
| Mean 2.63* | Mean 2.57*    | Mean 2.02* | Mean 2.33*   |              |
| SD 0.94  | SD 1.21        | SD 1.01 | SD 0.94     |              |
| Median 3.0 | Median 3.0   | Median 2.0 | Median 2.0    |              |
| IQR 2.0–3.0 | IQR 1.0–4.0 | IQR 1.0–3.0 | IQR 2.0–3.0  |              |

SD: standard deviation; IQR: interquartile range.

* $p<0.01$ with Bonferroni’s correction (Wilcoxon signed-rank test).

### Table IV. Treatment of chronic itch, $n$ (%)

| Treatment of chronic itch | $n=62$b |
|---------------------------|---------|
| | CS | CIs | OTT* | AIs | sCS | Cyc | OST | HOM | ACU | BIO | OAT |
| Topical treatments* | 37 (59.7) | 3 (4.8) | 30 (49.2) | 12 (19.4) | 1 (1.6) | 0 | 0 | 13 (21.0) | 1 (1.6) | 8 (12.9) | 9 (14.5) |
| Systemic treatments* | Total | | | | | | | | | | |

*Multiple responses possible. *bThree missing in “other topical therapy”.

CS: corticosteroids; CIs: calcineurin inhibitors; OTT: other topical treatment; AIs: antihistamines; sCS: systemic corticosteroids; Cyc: cyclosporine; OST: other systemic therapy; HOM: homeopathy; ACU: acupuncture; BIO: bioresonance; OAT: other alternative therapy.
The prevalence of itch in the general paediatric population is poorly investigated. This study adds new findings on the epidemiology of itch in schoolchildren.

Prevalence of AD among children is high across all continents and in Northern Europe, the prevalence is estimated to be approximately 15%. We speculate that the high prevalence of itch in the current study reflects the high prevalence of AD in children (5).

These findings are in line with those reported by Matterne et al. (12), who conducted a cross-sectional, questionnaire-based pilot study in 2009 and reported a chronic itch prevalence of 23%.

To the best of our knowledge, the mean itch intensity has not been previously assessed in a paediatric population. The current study showed a mean itch intensity of 2.61, which possibly reflects that a high proportion might have mild AD.

The location of itch has not been assessed in a general paediatric population. In this study, acute itch predominantly affected the head and folds of the arms, and chronic itch mainly affected the folds of the arms and legs. We speculate that the affected areas in the current study reflect the high prevalence of AD in the study population.

The inverse association between higher treatment intensity and QoL may be explained by the intensity of the treatment itself and the fact that more intense itch requires stronger treatment. (21). Since this study was performed, another group developed the KidsItchyQoL for 6–7-year-old children, which assesses the QoL related to itch, and 1 validation study was performed (19).

Most children with chronic itch were treated by a specialist physician, reflecting the high burden of itch. Interestingly, most patients reporting chronic itch were treated by a paediatrician or dermatologist, usually with topical treatment, but sometimes oral antihistamines were given. Surprisingly, oral glucocorticoids and alternative medicine were used, which does not comply with current guidelines and evidence (22, 23).

Strength and limitations

An advantage of the current study is that it assessed the sites of itch, timing of itch, and QoL. In addition, the study was population-based and included reasonably large numbers of participants. The assessment of content validity was beneficial. Chronic itch evaluated by the questionnaire was compared with information in hospital records; this was beneficial, as the prevalence and intensity of itch are patient-reported outcome measures, and there are currently no gold standards for children.

This study has some limitations. First, the study was performed in primary schools only in a single large city, which may have caused selection bias. The findings may be related to geographical, cultural, and/or socioeconomic factors. A multicentre study is warranted to confirm these findings. Secondly, the validation part of the current study was based on low numbers. However, the important parts of validation were performed. There was no indication that the questions were invalid, but these results should be interpreted with caution. Further validation studies with a larger study population in different regions are warranted. For the itch intensity, further studies are required to assess the possibility of a ceiling effect. A similar study on adults found a good correlation between the Numeric Rating Scale and a tool using visual assessment of the itch severity, which is encouraging (24). Regarding the assessment of itch-related quality of life, a limitation is the lack of a specific instrument validated for children at the time of study. We chose the ItchyQoL, which showed excellent validation properties in adults and was considered applicable by our expert panel. This choice is supported by a recent study using the tool in a validation study, which includes children with AD (25).

A major limitation of this study was the rather low participation rate, which potentially introduced selection bias. It cannot be excluded that children with itch may be over-represented in the current study, as they or their parents may be more willing to participate in such a study. Recall errors may occur when caregivers/children are asked to report chronic itch or the intensity and localization of itch on a questionnaire, which might have introduced recall bias.

The findings represent chronic itch in schoolchildren in Germany; however, the schoolchildren represent the general population of children well, and the results can thus be transferred to other western countries, especially in recognition of similar lifestyle, comparable psycho-social factors and access to healthcare system, all factors that also affect AD and associated symptoms, such as itch.

For excellent healthcare, it is important that the medical community and policymakers are aware that itch is a highly prevalent burdensome symptom. The need for a valid and reliable method to estimate the prevalence of itch in the general paediatric population is apparent, because itch is common in this population and not restricted to a single disease group. There is a clear need to focus on itch in schoolchildren. The results of this study can be used for optimizing guidelines, early intervention, and prevention.

Conclusion

This population-based study emphasizes the high prevalence of itch among schoolchildren and its association with impaired QoL. This study highlights the need for future research into chronic itch in other paediatric populations and settings.

ACKNOWLEDGEMENTS

We thank Melissa Crawford, PhD, from Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript.
The authors have no conflicts of interest to declare.

REFERENCES

1. Hay RJ, Johns NE, Williams HC, Bolliger IW, Dellavalle RP, Margolis DJ, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol 2014; 134: 1527–1534.

2. Ganemo A, Svensson A, Lindberg M, Wahlgren CF. Quality of life in Swedish children with eczema. Acta Derm Venereol 2007; 87: 345–349.

3. Weisshaar E, Dalgard F. Epidemiology of itch: adding to the burden of skin morbidity. Acta Derm Venereol 2009; 89: 339–350.

4. Halvorsen JA, Dalgard F, Thoresen M, Bjertness E, Lien L. Itch and mental distress: a cross-sectional study among late adolescents. Acta Derm Venereol 2009; 89: 39–44.

5. Bylund S, Kobyletzki LB, Svalstedt M, Svensson Å. Prevalence and incidence of atopic dermatitis: a systematic review. Acta Derm Venereol 2020; 100: adv0160.

6. Williams HC, Burney PG, Hay RJ, Archer CB, Shipley MJ, Hunter JJ, et al. The U.K. Working Party’s Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol 1994; 131: 383–396.

7. von Kobyletzki LB, Berner A, Carlstedt F, Hasselgren M, Bornehag CG, Svensson Å. Validation of a parental questionnaire to identify atopic dermatitis in a population-based sample of children up to 2 years of age. Dermatology 2013; 226: 222–226.

8. von Kobyletzki LB, Bornehag CG, Breeze E, Larsson M, Lindström CB, Svensson Å. Factors associated with remission of eczema in children: a population-based follow-up study. Acta Derm Venereol 2014; 94: 179–184.

9. Fang MM, Nowinski CJ, Lai J, Shaunfield S, Silverberg JI, Rangel SM, et al. Characteristics and impacts of itch in children with inflammatory skin disorders. Br J Dermatol 2012; 167: 896–904.

10. Matteyer U, Apfelbacher CJ, Loerbroks A, Schwarzer T, Buttner M, Ofenloch R, et al. Prevalence, correlates and characteristics of chronic pruritus: a population-based cross-sectional study. Acta Derm Venereol 2011; 91: 674–679.

11. Dalgard FJ, Svensson A, Halvorsen JA, Gieler U, Schüt C, Tomas-Aragones L, et al. Itch and mental health in dermatological patients across Europe: a cross-sectional study in 13 countries. J Invest Dermatol 2020; 140: 568–573.

12. Matteuer U, Strassner T, Apfelbacher CJ, Diepgen TL, Weisshaar E. Measuring the prevalence of chronic itch in the general population: development and validation of a questionnaire for use in large-scale studies. Acta Derm Venereol 2009; 89: 250–256.

13. Ständer S, Schäfer I, Phan NQ, Blome C, Herberger K, Heigel H, et al. Prevalence of chronic pruritus in Germany: results of a cross-sectional study in a sample working population of 11,730. Dermatology 2010; 221: 229–235.

14. Weisshaar E, Ständer S, Gieler U, Matteuer U, Darsow U. Entwicklung eines deutschsprachigen Fragebogens zur Erfassung von chronischem Pruritus (AGP- Fragebogen) Hintergrund und erste Ergebnisse. Hautarzt 2011; 62: 914–927.

15. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 1993; 186: 23–31.

16. Desai NS, PoinDEXTER GB, MonThePSE YM, Bendex SE, Swerlick RA, Chen SC. A pilot quality-of-life instrument for pruritus. J Am Acad Dermatol 2008; 59: 234–244.

17. Ständer S, Weisshaar E, Mettang T, Szepietowski JC, Carstens E, Ikoma A, et al. Clinical classification of itch: a position paper of the International Forum for the Study of Itch. Acta Derm Venereol 2007; 87: 291–294.

18. Ständer S, Zeidler C, Riepe C, Steinke S, Fritz F, Bruland P, et al. European EADV network on assessment of severity and burden of Pruritus (PruNet): first meeting on outcome tools. J Eur Acad Dermatol Venereol 2016; 30: 1144–1147.

19. Kong HE, Francois S, Smith S, Spraker M, Lawley LP, Lee G, et al. Pruritus assessment tools for 6 to 7-year-old children: KidsItchyQoL and ItchyQuant. Pediatr Dermatol 2021; 38: 591–601.

20. Krause K, Kessler B, Veidt J, Chen SC, Martus P, et al. German version of ItchyQoL: validation and initial clinical findings. Acta Derm Venereol 2013; 93: 562–568.

21. von Kobyletzki LB, Thomas KS, Schmitt J, Chalmers JR, Deckert S, Aoki V, et al. What factors are important to patients when assessing treatment response: an international cross-sectional survey. Acta Derm Venereol 2017; 97: 86–90.

22. Weisshaar E, Szepietowski JC, Dalgard FJ, Gavovich S, Gießer U, Gimenez-Arnau AM, et al. European S2k guideline on chronic pruritus. Acta Derm Venereol 2019; 99: 469–506.

23. Fölster-Holst R. Itch management in childhood. Curr Probl Dermatol 2016; 50: 173–191.

24. Phan NQ, Blome C, Fritz F, Gerss J, Reich A, Ebata T, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol 2012; 92: 502–507.

25. Silverberg JI, Lei D, Yousaf M, Jamnomedde SR, Vakharia PP, Chopra R, et al. Measurement properties of the product of investigator’s global assessment and body surface area in children and adults with atopic dermatitis. J Eur Acad Dermatol Venereol 2021; 35: 180–187.